Abstract:Background: Sepsis is mainly characterized by a dysregulated host response to infection and cytokine storm syndrome is one of the main pathogenic mechanisms of sepsis. Interleukin-3 (IL-3), a pro-inflammatory factor, has a multifaceted role in inflammatory diseases. However, its role in the pathogenesis of sepsis remains unknown.Methods: Serum levels of IL-3 were measured and analyzed in 38 Intensive Care Unit (ICU) patients with sepsis, 36 non-septic ICU patient controls, and 30 healthy volunteers. The effects of IL-3 on survival, inflammation, tissue damage, bacterial clearance, and the MAPK pathway were assessed using 2 male mouse models: cecum puncture and ligation (CLP)-induced sepsis and lipopolysaccharide (LPS)-induced sepsis.Results: Serum IL-3 levels were significantly higher in patients with sepsis on the day of diagnosis compared to ICU patient controls and healthy volunteers. Patients with septic shock showed significantly higher serum IL-3 levels compared to non-shocked patients. Serum interleukin-3 levels were correlated with sequential (sepsis-related) organ failure assessment scores (SOFA). Serum IL-3 level could discriminate septic shock from sepsis. Anti-IL-3 antibodies prolong survival time, recombinant IL-3 shortens survival time in two mouse models of CLP-induced sepsis and LPS-induced sepsis. Anti-IL-3 antibody application reduced inflammatory factor release (including IL-3, Interleukin-6 (IL-6), Interleukin1-β (IL-1β), and Tumor necrosis factor-α(TNF-α)); attenuated organ damage (including lung, liver, and kidney); enhanced bacterial clearance; attenuated splenic tissue inflammatory factor (including IL-3, IL-6, IL-1β, and TNF-α) protein content; and down-regulated phosphorylated p38, ERK, JNK protein content in MAPK pathway in lung, liver, and kidney. Recombinant IL-3 application promotes the release of inflammatory factors (including IL-3, IL-6, IL-1β, and TNF-α); exacerbates organ damage (including lung, liver, and kidney); reduces bacterial clearance; increases inflammatory factors (including IL-3, IL-6, IL-1-β, and TNF-α) protein content in splenic tissues; upregulates phosphorylated p38, ERK, JNK protein content in MAPK pathway in lung, liver, and kidney.Conclusions: Serum IL-3 levels are elevated in patients with sepsis, which may correlate with the severity of the disease. In experimental sepsis, we demonstrated that inhibition of IL-3 prolongs survival time, whereas IL-3 plays the opposite role. Anti-IL-3 may be a new target for sepsis treatment.

Protective effects of DcR3-SUMO on lipopolysaccharide-induced inflammatory cells and septic mice

Inhibitory mechanisms of decoy receptor 3 in cecal ligation and puncture-induced sepsis

Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis

S1PR3 Signaling Drives Bacterial Killing and is Required for Survival in Bacterial Sepsis.

Increased Susceptibility of S1PR3-Deficient Mice to Escherichia Coli Sepsis is Associated with an Impaired Bactericidal Activity in Macrophage

Protective Effect of Ginsenosides Rg1 and Re on Lipopolysaccharide-Induced Sepsis by Competitive Binding to Toll-like Receptor 4.

Sphingosine 1-Phosphate Receptor-3 Contributes to Host Defense Against Polymicrobial Sepsis Via Modulating Macrophage Chemotaxis (CAM4P.161)

Sphingosine 1-Phosphate Receptor-3 Enhances Pro-Inflammatory Activity in Human Monocytes (P1384)

Polyunsaturated fatty acid-derived lipid mediator Resolvin D1 alleviates sepsis-induced disseminated intravascular coagulation via Caspase-1/Gasdermin D pyroptotic pathway

Sphingosine 1-phosphate receptor-3 enhances pro-inflammatory activity in human monocytes

Protectin DX increases survival in a mouse model of sepsis by ameliorating inflammation and modulating macrophage phenotype

Resolvin D1 Promotes SIRT1 Expression to Counteract the Activation of STAT3 and NF-κB in Mice with Septic-Associated Lung Injury

A novel 1,2-benzenediamine derivative FC-99 suppresses TLR3 expression and ameliorates disease symptoms in a mouse model of sepsis

Inhibition of Interleukin-3 Reversed the Inflammatory Response and Organ Damage Induced by Sepsis

Dimethyl Fumarate Protects against Lipopolysaccharide- (LPS-) Induced Sepsis through Inhibition of NF-κB Pathway in Mice

The Protective Effects of Ruscogenin Against Lipopolysaccharide-Induced Myocardial Injury in Septic Mice

DcR3, a new biomarker for sepsis, correlates with infection severity and procalcitonin.

A novel benzenediamine derivate rescued mice from experimental sepsis by attenuating proinflammatory mediators via IRAK4.

The Antimicrobial Peptide Chensinin-1B Alleviates the Inflammatory Response by Targeting the TLR4/NF-κB Signaling Pathway and Inhibits Pseudomonas Aeruginosa Infection and LPS-mediated Sepsis.

GDF3 Protects Mice against Sepsis-Induced Cardiac Dysfunction and Mortality by Suppression of Macrophage Pro-Inflammatory Phenotype

A Cardiovascular Drug Rescues Mice from Lethal Sepsis by Selectively Attenuating a Late-Acting Proinflammatory Mediator, High Mobility Group Box 1